FDA rejects BioMarin's muscle-wasting disorder drug
January 14, 2016 at 08:37 AM EST
Jan 14 (Reuters) - BioMarin Pharmaceutical Inc said on Thursday the U.S. Food and Drug Administration had rejected its drug to treat a rare muscle-wasting disorder.